Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055732 | 1.00 | TACR1 (0.44) | TACR1TNFATMHTR1AGAA | |
| SCHEMBL3048360 | 0.92 | CYP3A4 (0.39) | TACR1TNFATMHTR1APPARG | |
| SCHEMBL3062581 | 0.92 | F2 (0.41) | TACR1TNFATMHTR1APPARG | |
| SCHEMBL3062715 | 0.92 | F2 (0.41) | TACR1TNFATMHTR1APPARG | |
| SCHEMBL3048342 | 0.92 | CYP3A4 (0.39) | TACR1TNFATMHTR1APPARG | |
| SCHEMBL3058113 | 0.91 | HCRTR1 (0.47) | HTR1AHCRTR1HCRTR2L3MBTL1MEN1 | |
| SCHEMBL3049767 | 0.91 | HCRTR1 (0.47) | HTR1AHCRTR1HCRTR2L3MBTL1MEN1 | |
| SCHEMBL3057212 | 0.89 | ACHE (0.48) | ATMHTR1AMAPTPPARGPPARA | |
| SCHEMBL3049985 | 0.89 | ACHE (0.48) | ATMHTR1AMAPTPPARGPPARA | |
| SCHEMBL3040824 | 0.88 | HCRTR1 (0.49) | GAAHCRTR1HCRTR2L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | claimed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | TACR1 1055/4885TNF 1789/4885ATM 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.